Highlights Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
45.76 ^USD	+3.11%		+0.09%	-23.95%

11:30am	Legend Expects to Log Profit in 2026	MT
May. 14	HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Legend Expects to Log Profit in 2026	05:30am	MT
Legend Biotech's Loss Narrows in Q1 as Revenue Surges	May. 14	MT
Sector Update: Health Care Stocks Decline Pre-Bell Monday	May. 13	MT
Sector Update: Health Care	May. 13	MT
Legend Biotech Q1 Net Loss Narrows as Revenue Rises; Shares Rise Pre-Bell	May. 13	MT
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales	May. 13	DJ
Earnings Flash (LEGN) LEGEND BIOTECH CORPORATION Reports Q1 Revenue $94M	May. 13	MT
Legend Biotech Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	Apr. 22	MT
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	Apr. 22	CI
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug	Apr. 17	MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	Apr. 08	MT
U.S. FDA approves expanded use of J&J's cancer cell therapy	Apr. 05	RE
Legend Biotech Corporation's CARVYKTI Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma	Apr. 05	CI
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	Apr. 05	RE
U.S. FDA allows expanded use of Bristol Myers' cell therapy	Apr. 05	RE
Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma	Mar. 15	CI
US FDA panel unanimously backs expanded use of J&J's CAR-T therapy	Mar. 15	RE
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies	Mar. 13	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Legend Biotech Corporation

Equities

LEGN

US52490G1022

Highlights

Filters